Onco Actu du 22 juillet 2015

	2. Etiologie
Night shifts 'linked to increased breast cancer risk' [NHS Choices] The researchers go as far as recommending that women with a known predisposition to breast cancer (such as having genetic mutations linked to breast cancer) should avoid shift work. But, obviously, not everyone has the luxury of picking and choosing what hours they work.
	2.4 Etiologie - Portables, ondes e-m
Cellphone Ordinance Puts Berkeley at Forefront of Radiation Debate [NY Times] If cellphones were carcinogenic, Dr. Bushberg said, researchers would have seen an increase in brain cancer in Scandinavian countries, where cellphones have been used longer and where, because of socialized medicine, excellent cancer registries exist. That has not happened, he said.
	3.1 Tabac
More evidence smoking raises risk of death from breast cancer [Reuters] Among more than 800 women with breast cancer, those who had smoked for more than two decades had at least triple the odds of dying of any cause, or from breast cancer in particular, compared with women who never used cigarettes.
	4.2 Dép., diag. & prono. - Génome
HL7 Genomics Policy Conference [HL7] Accessing the Code: Interoperability, Genetic Information and Precision Patient Care.
	5.2 Pharma
AstraZeneca provides update on selumetinib in uveal melanoma [AstraZeneca] AstraZeneca today announced that the Phase III SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival.
Novartis bullish on Afinitor cancer drug despite new competition [Reuters] "If Opdivo is approved in renal cell cancer, it will probably delay use of Afinitor in that particular indication," Novartis Chief Executive Joe Jimenez told reporters in a results call on Tuesday. "But because this is a multi-indication drug we still are bullish on Afinitor's growth prospects."
	5.2.1 Pharma - Partenariats
Where Should Pharma Hunt For Academic Innovation? [Forbes] Throwing unrestricted funds at academia’s best-known research centers is a symptom of low creativity in pharma R&D – a safe, straight-down-the-middle bet, designed to neither awe nor disappoint, and also, like hiring McKinsey as your consulting firm, guaranteed not to ruffle any feathers. Isn’t there a better way?
	5.2.3 Pharma - économie
Biotech Investing Hits An All-Time High--But Is It A Bubble? [Forbes] The mapping of the human genome in the early 2000s helped drive the earlier boom—and the resulting bust—because investors assumed it would lead to medical advances much more quickly than it did. “We thought it was going to be magic,” Gordon says. “Now we’re a little more realistic. We no longer expect that a genetic sequence will tell us everything we need to know.”
	5.4 Traitements - Economie
How High? The Backlash Over Rising Prescription Drug Prices Gains Steam [Wall Street Journal] Taken together, these developments underscore how the cost of medicines has come to captivate Americans and spark a growing clamor for change.
Government review describes NICE as a “respected, trusted, high performing organisation” [NICE] The review looked at what NICE does, if it is necessary and, if so, whether any aspects could be better delivered by another organisation. The review also considered NICE’s impact, communications and relationships, efficiency and governance.
	6. Lutte contre les cancers
MD Anderson named top-ranked hospital for cancer care [MD Anderson Cancer Center] Since the annual survey launched in 1990, MD Anderson has been named one of the top two cancer hospitals in the United States. It has ranked first 11 times in the past 14 years.
	6.11 Patients
‘Laughing helps you get through it’ – Rowena’s story [Cancer Research UK] Rowena is 39 and has terminal cancer. She started to worry about the fact that she didn’t have a ‘bucket list’, and wasn’t sure if she needed one. Over the last year, she’s been meeting other young people with a terminal diagnosis, to find out how they feel, and how they’re coming to terms with their prognosis.
'We fish, laugh and eat': the breast cancer survivors learning how to fly-fish [The Guardian] “Having cancer has definitely woken me up to life, and the beauty of my surroundings,” she says. “I struggle with [fears] of recurrence or metastasis – but for the hour or two that I’m fly-fishing, I can let go of some of those worries. For me, it’s ‘quiet time’ that actually remains quiet.”
	6.8 Communication
"Bring your brave" angers some in breast cancer community [HealthNewsReview] “This is another example of using the war imagery to promote awareness. What happens when you don’t feel brave? Why the hyper-focus on BRCA/previvor issues when metastatic continually gets swept under the rug? … I think it falls way short of what the CDC could and should be doing.”